Table 1.
Pt. Id | age | Meno-pause | Breast Density | Initial Path. (ER/PR/Her2) | Size/ROI (mm) | Treatment regimen | Surgical path. |
---|---|---|---|---|---|---|---|
1 | 36 | neg | S | IDC/DCIS ER+/PR−/Her2+ |
65×37×71 | TAC | pCR |
2 | 51 | pos | S | IDC ER−/PR−/Her2− |
44×32×43 | TAC | pCR |
3 | 41 | neg | H | IDC ER+/PR+/Her2+ |
53×22×50 | TAC | pCR |
4 | 30 | neg | H | IDC ER−/PR−/Her2− |
36 | TAC | pCR |
5 | 52 | pos | H | IDC ER−/PR−/Her2+ |
100×70×50 | FEC-Herceptin/Taxol-Herceptin | pCR |
6 | 63 | pos | H | IDC/DCIS ER+/PR+/Her2+ |
90×70×40 | TAC | pCR |
7 | 60 | pos | S | IDC/DCIS ER−/PR−/Her2+ |
39×26×42 | Taxol-Herceptin/FEC-Herceptin | pCR |
8 | 52 | neg | E | IDC ER−/PR−/Her2− |
34×45×100 | TAC | pCR |
9 | 66 | pos | H | IDC/DCIS ER−/PR−/Her2+ |
59×43×53 | Taxol-Herceptin/FEC-Herceptin | pCR |
10 | 30 | neg | H | IDC ER−/PR−/Her2− |
40×26×40 | Taxol | pIR |
11 | 52 | neg | E | IDC ER+/PR+/Her2− |
58×34×45 | Taxol | pIR |
12 | 62 | pos | H | IDC ER+/PR+/Her2− |
70×50×50 | Adriamycin/cyclophosphamide/taxotere | pIR |
13 | 70 | pos | S | IDC/DCIS ER−/PR−/Her2+ |
63×28×30 | Taxol-Herceptin/FEC-Herceptin | pIR |
14 | 53 | neg | E | ILC ER+/PR+/Her2− |
76×45×79 | TAC | pIR |
15 | 27 | neg | H | IDC ER+/PR+/Her2− |
61×18×41 | TAC | pIR |
16 | 53 | neg | H | IDC ER+/PR+/Her2+ |
62×46×87 | Taxol-Herceptin/FEC-Herceptin | pIR |
17 | 50 | neg | H | IDC ER+/PR+/Her2+ |
40 | Abraxane/Avastin | pIR |
18 | 56 | pos | H | IDC ER+/PR+/Her2+ |
55×34×52 | TAC | pIR |
19 | 38 | neg | S | IDC/DCIS ER+/PR+/Her2− |
84×93×50 | TAC | pIR |
Breast Density- S: scatter; H: Heterogamous dense; E: extremely dense. Initial pathological results- IDC: invasive ductal carcinoma; DCIS: ductal carcinoma in situ.